drugset / Trial / NCT00288223

Telithromycin in Acute Exacerbation of Chronic Bronchitis

NCT00288223

Phase 4 Terminated 54 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study objectives: * to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis. * to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3) * to assess the safety of telithromycin

Timeline

Start
2006-01
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Telithromycin Small molecule 800 mg Oral

Indications